Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher-Paul Milne

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinical Therapeutics|September 25, 2017
The Use of Social Media in Orphan Drug DevelopmentChristopher-Paul Milne, Wendi Ni
Food and Drug Law Journal|November 27, 2008
Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?Laura B Faden, Christopher-Paul Milne
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
Science Translational Medicine|April 7, 2010
Translational medicine: an engine of change for bringing new technology to community healthChristopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|December 26, 2008
The economics of pediatric formulation development for off-patent drugsChristopher-Paul Milne, Jon B Bruss
Clinical Therapeutics|November 1, 2018
Regenerative Medicine at the Forefront of Innovation: Update From JapanChristopher-Paul Milne, Kenneth I Kaitin
Frontiers in Pharmacology|March 26, 2019
Are Regulation and Innovation Priorities Serving Public Health Needs?Christopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|July 15, 2018
Challenge and Change at the Forefront of Regenerative MedicineChristopher-Paul Milne, Kenneth I Kaitin
American Journal of Therapeutics|December 23, 2009
Private sector contributions to pharmaceutical science: thirty-five summary case historiesBenjamin Zycher, Joseph A DiMasi, Christopher-Paul Milne
Nature Reviews. Drug Discovery|October 17, 2015
Market watch: Where is personalized medicine in industry heading?Christopher-Paul Milne, Joshua P Cohen, Ranjana Chakravarthy
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Therapeutics|September 25, 2017
The Use of Social Media in Orphan Drug DevelopmentChristopher-Paul Milne, Wendi Ni
Food and Drug Law Journal|November 27, 2008
Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?Laura B Faden, Christopher-Paul Milne
American Journal of Therapeutics|November 9, 2002
Public and private sector contributions to the discovery and development of "impact" drugsJanice M Reichert, Christopher-Paul Milne
Science Translational Medicine|April 7, 2010
Translational medicine: an engine of change for bringing new technology to community healthChristopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|December 26, 2008
The economics of pediatric formulation development for off-patent drugsChristopher-Paul Milne, Jon B Bruss
Clinical Therapeutics|November 1, 2018
Regenerative Medicine at the Forefront of Innovation: Update From JapanChristopher-Paul Milne, Kenneth I Kaitin
Frontiers in Pharmacology|March 26, 2019
Are Regulation and Innovation Priorities Serving Public Health Needs?Christopher-Paul Milne, Kenneth I Kaitin
Clinical Therapeutics|July 15, 2018
Challenge and Change at the Forefront of Regenerative MedicineChristopher-Paul Milne, Kenneth I Kaitin
American Journal of Therapeutics|December 23, 2009
Private sector contributions to pharmaceutical science: thirty-five summary case historiesBenjamin Zycher, Joseph A DiMasi, Christopher-Paul Milne
Nature Reviews. Drug Discovery|October 17, 2015
Market watch: Where is personalized medicine in industry heading?Christopher-Paul Milne, Joshua P Cohen, Ranjana Chakravarthy
Pageof 3